Recylex S.A.

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, XVALO.MC has a market cap of 36.9B. Regarding current trading prices, RX.PA is priced at €1.85, while XVALO.MC trades at €8.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas XVALO.MC's P/E ratio is 7.20. In terms of profitability, RX.PA's ROE is -1.21%, compared to XVALO.MC's ROE of +0.16%. Regarding short-term risk, RX.PA is less volatile compared to XVALO.MC. This indicates potentially lower risk in terms of short-term price fluctuations for RX.PA.Check XVALO.MC's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, ERA.PA has a market cap of 1.4B. Regarding current trading prices, RX.PA is priced at €1.85, while ERA.PA trades at €47.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas ERA.PA's P/E ratio is -14.08. In terms of profitability, RX.PA's ROE is -1.21%, compared to ERA.PA's ROE of +0.01%. Regarding short-term risk, RX.PA is more volatile compared to ERA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for RX.PA.Check ERA.PA's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, AMG.AS has a market cap of 777M. Regarding current trading prices, RX.PA is priced at €1.85, while AMG.AS trades at €24.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas AMG.AS's P/E ratio is 86.00. In terms of profitability, RX.PA's ROE is -1.21%, compared to AMG.AS's ROE of -0.02%. Regarding short-term risk, RX.PA is less volatile compared to AMG.AS. This indicates potentially lower risk in terms of short-term price fluctuations for RX.PA.Check AMG.AS's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, KMR.IR has a market cap of 343.1M. Regarding current trading prices, RX.PA is priced at €1.85, while KMR.IR trades at €3.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas KMR.IR's P/E ratio is 6.26. In terms of profitability, RX.PA's ROE is -1.21%, compared to KMR.IR's ROE of +0.05%. Regarding short-term risk, RX.PA is less volatile compared to KMR.IR. This indicates potentially lower risk in terms of short-term price fluctuations for RX.PA.Check KMR.IR's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, MLZAM.PA has a market cap of 27.7M. Regarding current trading prices, RX.PA is priced at €1.85, while MLZAM.PA trades at €1.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas MLZAM.PA's P/E ratio is 0.20. In terms of profitability, RX.PA's ROE is -1.21%, compared to MLZAM.PA's ROE of +1.06%. Regarding short-term risk, RX.PA is less volatile compared to MLZAM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for RX.PA.Check MLZAM.PA's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, NYR.BR has a market cap of 7.6M. Regarding current trading prices, RX.PA is priced at €1.85, while NYR.BR trades at €0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas NYR.BR's P/E ratio is -1.73. In terms of profitability, RX.PA's ROE is -1.21%, compared to NYR.BR's ROE of +0.26%. Regarding short-term risk, RX.PA is less volatile compared to NYR.BR. This indicates potentially lower risk in terms of short-term price fluctuations for RX.PA.Check NYR.BR's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, ORQ1.IR has a market cap of 3.3M. Regarding current trading prices, RX.PA is priced at €1.85, while ORQ1.IR trades at €0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas ORQ1.IR's P/E ratio is N/A. In terms of profitability, RX.PA's ROE is -1.21%, compared to ORQ1.IR's ROE of -0.58%. Regarding short-term risk, RX.PA is less volatile compared to ORQ1.IR. This indicates potentially lower risk in terms of short-term price fluctuations for RX.PA.Check ORQ1.IR's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, 8GW.IR has a market cap of 2M. Regarding current trading prices, RX.PA is priced at €1.85, while 8GW.IR trades at €0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas 8GW.IR's P/E ratio is -0.29. In terms of profitability, RX.PA's ROE is -1.21%, compared to 8GW.IR's ROE of -0.00%. Regarding short-term risk, RX.PA is more volatile compared to 8GW.IR. This indicates potentially higher risk in terms of short-term price fluctuations for RX.PA.Check 8GW.IR's competition here

RX.PA plays a significant role within the Basic Materials sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RX.PA stands at 47.8M. In comparison, MLSUM.PA has a market cap of 102K. Regarding current trading prices, RX.PA is priced at €1.85, while MLSUM.PA trades at €0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RX.PA currently has a P/E ratio of 0.38, whereas MLSUM.PA's P/E ratio is N/A. In terms of profitability, RX.PA's ROE is -1.21%, compared to MLSUM.PA's ROE of -0.23%. Regarding short-term risk, RX.PA is more volatile compared to MLSUM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for RX.PA.Check MLSUM.PA's competition here